×
CV Sciences Operating Expenses 2011-2024 | CVSI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CV Sciences operating expenses from 2011 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
CV Sciences Operating Expenses 2011-2024 | CVSI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CV Sciences operating expenses from 2011 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$43.8B
Merck (MKKGY)
$21B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.8B
United Therapeutics (UTHR)
$18.3B
Summit Therapeutics (SMMT)
$15.8B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.8B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Orion OYJ (ORINY)
$6.8B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$6.2B
Crinetics Pharmaceuticals (CRNX)
$4.9B
PTC Therapeutics (PTCT)
$3.4B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.9B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B